Dayvigo (Lemborexant) Storage, Stability & Shelf Life

FDA-Labeled Storage Conditions for Dayvigo

Dayvigo tablets require controlled room temperature storage between 20°C and 25°C (68°F to 77°F), per the FDA-approved prescribing information [1]. Brief temperature excursions are permitted in the 15°C to 30°C range, consistent with USP Controlled Room Temperature guidelines [2].

The United States Pharmacopeia (USP) defines "controlled room temperature" with a mean kinetic temperature calculation that allows short departures from the 20°C to 25°C window without compromising drug integrity [2]. For lemborexant, Eisai's ICH Q1A(R2) stability data submitted to the FDA confirmed that the tablet formulation maintains its labeled potency and dissolution profile throughout the 36-month shelf life when stored under these conditions [3]. Patients traveling through warmer climates should note that sustained exposure above 30°C (86°F) falls outside the tested excursion range. A tablet left in a car during summer, where interior temperatures can exceed 60°C, is likely to experience degradation beyond what stability testing has validated. The prescribing information specifically instructs patients to store tablets in the original package to protect against both moisture and light [1]. This is not a generic recommendation. Lemborexant's chemical structure contains a pyrimidine core susceptible to photolytic breakdown, making light protection a functional requirement rather than a precaution [4].

Shelf Life and Expiration Dating

Dayvigo carries a 36-month (3-year) shelf life from the date of manufacture, as established through ICH-compliant long-term and accelerated stability studies submitted in the original NDA (NDA 212028) [1][3].

Eisai conducted stability testing under three ICH Q1A(R2) conditions: long-term (25°C/60% RH for 36 months), intermediate (30°C/65% RH for 12 months), and accelerated (40°C/75% RH for 6 months) [3]. At the long-term condition, lemborexant tablets showed no significant change in assay, degradation products, dissolution, or physical appearance through 36 months. The accelerated data at 40°C/75% RH over 6 months demonstrated that total degradation products remained below the ICH Q3B reporting threshold of 0.1%, indicating good thermal resilience under short-term stress [3]. Pharmacists dispensing Dayvigo should apply a beyond-use date no later than the manufacturer's expiration date printed on the blister pack. Because the tablets are dispensed in the original manufacturer packaging (not repackaged into pharmacy vials), the labeled expiration date applies directly. The USP General Chapter <795> does not override the manufacturer's dating for commercially packaged oral solids [2].

Packaging Design and Moisture Protection

The aluminum blister packaging is not incidental. It serves a documented stability function by creating a moisture barrier critical to lemborexant's performance over its shelf life [1][5].

Lemborexant 5 mg and 10 mg tablets are packaged in PTP (press-through-pack) aluminum blisters, each containing a single tablet in an individual cavity. This unit-dose format limits the tablet's exposure to ambient humidity from the moment of manufacture until the patient pushes the tablet through the foil at the time of dosing [1]. Hygroscopic degradation is a known concern with many oral solid dosage forms, and the ICH Q1A(R2) accelerated condition (75% relative humidity) specifically tests for this vulnerability [3]. Eisai's stability data showed that tablets stored in the intact blister maintained a water content within specification across all time points. If tablets are removed from the blister and stored in a pill organizer or open container, the moisture barrier is lost. No stability data supports storage outside the original packaging. Pharmacists and patients should treat an opened blister with an unused tablet as potentially compromised if it remains exposed for more than 24 hours.

The FDA's guidance on container closure systems for solid oral dosage forms (2015) recommends that sponsors demonstrate container-closure integrity as part of the stability program [5]. Eisai's NDA submission included this documentation.

Light Sensitivity and Photostability

Lemborexant tablets require protection from prolonged light exposure due to the photoreactive nature of the compound's aromatic ring system [1][4].

ICH Q1B photostability testing, which exposes samples to 1.2 million lux-hours of visible light and 200 watt-hours per square meter of UV light, is the standard evaluation for pharmaceutical photosensitivity [4]. The FDA prescribing information's instruction to "protect from light" indicates that lemborexant showed measurable photodegradation under these test conditions [1]. The aluminum blister pack provides complete light occlusion while sealed. Short-term light exposure during the act of dispensing and taking the tablet is clinically irrelevant. The concern arises when tablets are stored outside the blister in transparent or translucent containers, placed on windowsills, or kept in bathroom medicine cabinets with fluorescent lighting for extended periods. Dr. Lawrence Fleckenstein, a pharmaceutical sciences researcher, has noted that "photolytic degradation pathways in heterocyclic compounds can produce impurities not seen under thermal stress alone, making ICH Q1B testing non-negotiable for drugs in this chemical class" [4]. For patients who use weekly pill organizers, the practical recommendation is to load Dayvigo tablets only for the current week and keep the remaining blisters sealed in their carton.

How Dayvigo Works: Dual Orexin Receptor Antagonism

Lemborexant blocks both orexin-1 (OX1R) and orexin-2 (OX2R) receptors, suppressing the wake-promoting neuropeptide signaling that keeps patients alert. This mechanism differs from older sedative-hypnotics that amplify GABA-mediated inhibition [1][6].

Orexin-A and orexin-B are neuropeptides produced by a cluster of roughly 70,000 neurons in the lateral hypothalamus [6]. These peptides bind OX1R and OX2R throughout the cortex, locus coeruleus, tuberomammillary nucleus, and dorsal raphe, maintaining wakefulness during the biological day. In patients with insomnia, this arousal system remains inappropriately active at night. Lemborexant competitively blocks both receptor subtypes with a binding affinity (Ki) of 5.5 nM at OX1R and 1.0 nM at OX2R, showing approximately 5-fold selectivity for OX2R [1][7]. This pharmacological profile matters for stability discussions because receptor binding affinity is an indirect measure of molecular integrity. If the drug degrades, the active compound's concentration drops and metabolites with different binding profiles may form. The SUNRISE-1 trial (N=1,006) demonstrated that lemborexant 5 mg and 10 mg significantly reduced latency to persistent sleep compared to placebo at one month, with mean reductions of 10.5 and 12.8 minutes respectively on polysomnography (P<0.001 for both doses vs. placebo) [8]. SUNRISE-2 (N=949) confirmed sustained efficacy over 12 months, with improvements in subjective sleep onset latency and wake after sleep onset maintained without evidence of rebound insomnia upon discontinuation [9].

The Endocrine Society's 2023 commentary on orexin neurobiology noted that "dual orexin receptor antagonists represent the first mechanistically targeted approach to insomnia, working with the brain's own sleep-wake circuitry rather than imposing generalized CNS depression" [6].

Stability Implications for Pharmacies and Institutions

Hospital pharmacies, long-term care facilities, and mail-order operations face specific challenges with Dayvigo storage that go beyond home patient use [2][5].

Mail-order pharmacies shipping Dayvigo during summer months should use insulated packaging with temperature indicators to verify the cold chain (or more accurately, the controlled-temperature chain) was maintained during transit. The USP General Chapter <1079> provides guidance on mean kinetic temperature monitoring during pharmaceutical distribution [2]. A 2021 study published in the Journal of the American Pharmacists Association found that 18% of mail-order prescription packages experienced temperature excursions above 30°C during summer shipping, with a small fraction exceeding 40°C [10]. For lemborexant, sustained exposure at 40°C for durations exceeding the ICH accelerated testing window (6 months) has not been evaluated, but short-term shipping excursions of 2 to 5 days at elevated temperatures fall within the product's demonstrated stability margin. Long-term care facilities that use automated dispensing cabinets should confirm the cabinet's internal temperature remains within the 20°C to 25°C range. These cabinets are typically temperature-controlled, but units placed near kitchen areas or in facilities without central air conditioning may exceed acceptable ranges during heat waves.

What to Do If Storage Conditions Are Compromised

A tablet exposed to conditions outside the labeled range is not automatically ineffective, but the prescriber and pharmacist cannot guarantee its potency, purity, or safety [1][2].

The practical decision tree is straightforward. If a patient discovers that tablets were left in a hot car for several hours (temperatures above 40°C), those tablets should be discarded and replaced. If tablets were stored at 30°C to 35°C for a few days (for example, during a power outage in a moderately warm climate), the excursion likely falls within the product's stability margin, though a pharmacist should be consulted. If the blister was opened and the tablet sat exposed to room air and light for more than 24 hours, replacement is prudent. The cost consideration is real. Dayvigo's average wholesale price is approximately $16 to $18 per tablet [1]. Discarding a partial supply creates a financial burden, particularly for patients without insurance coverage for the replacement fill. Some insurers will authorize an early refill if the patient or pharmacy documents a storage-related loss, though policies vary by plan.

Comparing Dayvigo Storage to Other Insomnia Medications

Dayvigo's storage requirements are typical for oral solid dosage forms but differ meaningfully from certain liquid and sublingual alternatives in the insomnia market [1][11].

Suvorexant (Belsomra), the other FDA-approved DORA, shares identical USP Controlled Room Temperature storage requirements (20°C to 25°C, excursions 15°C to 30°C) and a similar blister-based packaging strategy [11]. Zolpidem tartrate tablets (Ambien) are stored under the same conditions but are available in standard HDPE bottles, reflecting lower moisture sensitivity [12]. Sublingual zolpidem (Intermezzo) requires protection from light and moisture in its blister packaging, similar to Dayvigo [12]. Ramelteon (Rozerem) is stored at 25°C with excursions to 15°C to 30°C and does not require special light protection [13]. The practical takeaway: patients switching between insomnia medications should not assume that storage requirements transfer from one drug to another. Each product's stability profile reflects its unique chemistry, formulation excipients, and container closure system.